UroGen Pharma Ltd. URGN

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our approved products Jelmyto (mitomycin) for pyelocalyceal solution and Zusduri (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer ("low-grade UTUC") and recurrent low-grade intermediate risk non-muscle invasive bladder cancer ("low-grade intermediate risk NMIBC"), respectively. In addition, our immuno-uro-oncology pipeline includes UGN-501 (formerly known as ICVB-1042), a next-generation investigational oncolytic virus.

Last close 34.49 2026-10-23
Market cap $1.69B 2026-06-30 share count
52-week range 16.50 - 50.81

Valuation FY2025 figures against the last close

P/S15.4x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $109.8M$90.4M$82.7M$64.4M$48.0M$11.8M$18.0K$1.1M$8.2M$17.5M
Cost of revenue $12.4M$8.9M$9.4M$7.7M$5.2M$1.0M—$1.8M$600.0K$28.0K
Gross profit $97.3M$81.5M$73.4M$56.7M$42.9M$10.8M$18.0K-$675.0K$7.6M$17.5M
R&D $67.1M$57.1M$45.6M$52.9M$47.6M$47.3M$49.3M$36.9M$18.7M—
SG&A $155.1M$121.2M$93.3M$82.8M$87.5M$90.2M$60.2M$39.6M$8.8M$6.4M
Total operating expenses ——————$109.5M$76.5M$27.5M—
Operating income -$124.9M-$96.8M-$65.5M-$79.0M-$92.3M-$126.7M-$109.5M-$77.2M-$19.9M$798.0K
Pre-tax income -$153.4M-$124.0M-$98.3M-$108.0M-$109.4M-$125.1M-$105.1M-$75.5M-$20.0M-$1.9M
Income tax $78.0K$2.8M$3.9M$1.8M$1.4M$3.4M—$125.0K$19.0K—
Net income -$153.5M-$126.9M-$102.2M-$109.8M-$110.8M-$128.5M-$105.1M-$75.7M-$20.0M-$1.9M
EPS, basic -3.19-2.96-3.55-4.81-4.96—————
EPS, diluted ————-4.96-5.90-5.12-4.80-2.14-1.91
Shares, diluted (wtd. avg.) 48.1M42.9M28.8M22.8M22.3M—————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $110.7M$172.0M$95.0M$55.4M$44.4M$52.9M$49.7M$101.3M$37.0M$21.4M
Short-term investments $49.3M$110.7M$56.2M$44.6M$44.8M$49.2M$97.4M—$36.0M—
Receivables $33.1M$20.3M$15.4M$12.7M$11.7M$7.0M———$83.0K
Inventory $16.5M$9.2M$5.7M$4.3M$4.8M$2.0M——$316.0K$105.0K
Total current assets $186.0M$276.1M$169.2M$128.9M$114.4M$115.6M$148.6M$102.2M$74.5M$22.0M
Property, plant and equipment $637.0K$655.0K$689.0K$1.3M$2.0M$2.0M$977.0K$948.0K$805.0K$741.0K
Total assets $200.5M$285.7M$178.3M$135.6M$119.7M$122.0M$202.4M$103.6M$75.5M$23.1M
Accounts payable $12.1M$10.9M$6.5M$5.5M$5.8M$3.3M$4.7M$4.3M$2.8M$1.9M
Total current liabilities $46.4M$45.9M$31.2M$23.9M$22.4M$21.4M$19.5M$13.5M$7.0M$3.1M
Long-term debt $122.2M$121.7M$98.6M$97.5M$0—————
Total liabilities $305.9M$294.5M$243.5M$225.0M$111.3M$25.6M$22.1M$13.5M$7.0M$6.7M
Retained earnings -$959.7M-$806.2M-$679.3M-$577.1M-$467.3M-$356.5M-$228.0M-$122.9M-$47.2M-$27.2M
Total equity -$105.5M-$8.8M-$65.2M-$89.4M$8.4M$96.4M$180.3M$90.1M$68.5M$16.3M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$162.4M-$96.8M-$76.4M-$87.6M-$84.9M-$105.9M-$71.0M-$37.3M-$9.6M$4.2M
Depreciation and amortisation $307.0K$329.0K$802.0K$924.0K$831.0K$416.0K$300.0K$400.0K$200.0K$200.0K
Stock-based compensation $12.0M$13.1M$9.3M$10.6M$23.1M$28.0M$30.0M$30.6M$6.3M$2.0M
Capital expenditure $289.0K$295.0K$194.0K$254.0K$752.0K$1.2M$325.0K$560.0K$271.0K$695.0K
Investing cash flow $61.6M-$20.6M-$953.0K$1.1M$4.1M$93.2M-$145.6M$35.3M-$36.3M-$719.0K
Financing cash flow $39.9M$194.6M$116.9M$97.1M$72.3M$16.5M$165.2M$66.4M$61.6M-$9.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-014237.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M -100M 0 100M 200M Revenue, FY2016: 17.5M Gross profit, FY2016: 17.5M Net income, FY2016: -1.9M Revenue, FY2017: 8.2M Gross profit, FY2017: 7.6M Net income, FY2017: -20M Revenue, FY2018: 1.1M Gross profit, FY2018: -675K Net income, FY2018: -75.7M Revenue, FY2019: 18K Gross profit, FY2019: 18K Net income, FY2019: -105.1M Revenue, FY2020: 11.8M Gross profit, FY2020: 10.8M Net income, FY2020: -128.5M Revenue, FY2021: 48M Gross profit, FY2021: 42.9M Net income, FY2021: -110.8M Revenue, FY2022: 64.4M Gross profit, FY2022: 56.7M Net income, FY2022: -109.8M Revenue, FY2023: 82.7M Gross profit, FY2023: 73.4M Net income, FY2023: -102.2M Revenue, FY2024: 90.4M Gross profit, FY2024: 81.5M Net income, FY2024: -126.9M Revenue, FY2025: 109.8M Gross profit, FY2025: 97.3M Net income, FY2025: -153.5M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $17.5M $8.2M $1.1M $18.0K $11.8M $48.0M $64.4M $82.7M $90.4M $109.8M
Gross profit $17.5M $7.6M -$675.0K $18.0K $10.8M $42.9M $56.7M $73.4M $81.5M $97.3M
Net income -$1.9M -$20.0M -$75.7M -$105.1M -$128.5M -$110.8M -$109.8M -$102.2M -$126.9M -$153.5M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event Item 8.01
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced Item 2.02
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%